Cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), programmed death 1 (PD-1), and programmed cell death 1 ligand 1 (PD-L1) inhibitors had shown good safety and efficacy in various tumor types, including genitourinary oncology, gastrointestinal oncology, and hematologic tumor (1). Here, CTLA4 is linked to neoplasm.